Chondrodysplasia – Causes, Symptoms and Treatment

What is Chondrodysplasia?

Chondrodysplasia describes a large and heterogeneous group of genetically caused skeletal dysplasias in which the normal formation and growth of cartilage and bone tissue is disrupted. The term derives from the Greek chondros (cartilage) and dysplasia (abnormal formation). These conditions typically result in short stature, skeletal deformities, and various structural abnormalities of the musculoskeletal system.

Chondrodysplasias are classified as rare diseases and encompass more than 400 distinct forms, differing in severity, skeletal regions affected, and underlying genetic causes. The most well-known form is achondroplasia, the most common cause of disproportionate short stature in humans.

Causes

Chondrodysplasias are caused by mutations in genes essential for cartilage and bone development. Most forms are inherited in an autosomal dominant or autosomal recessive pattern, with X-linked inheritance being less common.

• Achondroplasia: Mutation in the FGFR3 gene (fibroblast growth factor receptor 3), most often arising as a de novo mutation
• Hypochondroplasia: Also caused by FGFR3 mutations, but with a milder phenotype
• Spondyloepiphyseal dysplasia: Mutations in the COL2A1 gene (type II collagen)
• Diastrophic dysplasia: Mutations in the SLC26A2 gene (sulfate transporter)
• Metaphyseal chondrodysplasia: Various gene mutations depending on subtype, e.g., PTHR1 or RMRP mutations

In some cases, mutations arise spontaneously (de novo) without a family history. Advanced paternal age is a recognized risk factor for certain de novo mutations.

Symptoms

The clinical presentation varies considerably depending on the subtype. Common shared features include:

• Short stature (proportionate or disproportionate depending on the form)
• Shortened limbs, particularly the long bones (rhizomelia, mesomelia, or acromelia)
• Spinal deformities (scoliosis, kyphosis, lumbar lordosis)
• Restricted joint mobility or joint hypermobility
• Broad, short hands and fingers (trident hand in achondroplasia)
• Coarse facial features in certain subtypes
• Neurological complications, e.g., spinal canal stenosis with numbness or weakness
• Recurrent middle ear infections and hearing impairment (especially in achondroplasia)

In severe forms such as thanatophoric dysplasia, the condition is perinatally lethal due to insufficient lung development.

Diagnosis

The diagnosis of chondrodysplasia is based on a combination of clinical examination, imaging studies, and molecular genetic testing.

Prenatal Diagnosis

• Ultrasound examination: Shortening of long bones, macrocephaly, and other skeletal abnormalities may be detected from the second trimester onward
• Molecular genetic analysis of amniotic fluid (amniocentesis) or chorionic villus sampling when a familial mutation is known

Postnatal Diagnosis

• Physical examination and anthropometric measurements (height, body proportions)
• Full skeletal X-ray survey: characteristic changes in metaphyses, epiphyses, and vertebrae
• MRI of the skull and spine for neurological symptoms
• Molecular genetic testing to identify the causative gene mutation
• Biochemical testing when a metabolic disorder is suspected

Treatment

There is currently no curative therapy for most forms of chondrodysplasia. Treatment is symptomatic and focused on preventing complications, improving quality of life, and supporting normal development as much as possible.

Medical Therapy

• Vosoritide (Voxzogo): A CNP analogue (C-type natriuretic peptide) approved in the EU in 2021 for children with achondroplasia aged 2 years and older. It inhibits the overactivated FGFR3 signaling pathway and promotes longitudinal bone growth.
• Growth hormone therapy: In specific forms with confirmed growth hormone deficiency

Surgical Therapy

• Limb lengthening procedures (callus distraction): Gradual lengthening of long bones by distraction of callus tissue
• Spinal canal decompression for cervical or lumbar stenosis with neurological symptoms
• Correction of limb axis deformities (osteotomies)
• Treatment of hydrocephalus by placement of a shunt

Physiotherapy and Rehabilitation

• Physical therapy to strengthen trunk and limb musculature
• Occupational therapy to promote independence in daily activities
• Orthopedic aids (insoles, orthoses)

Multidisciplinary Care

Given the wide range of potential complications, long-term interdisciplinary care involving orthopedics, neurology, ENT, pediatrics, and medical genetics is essential. Psychosocial support and patient advocacy organizations also play an important role.

Prognosis

Life expectancy is near normal for most milder forms of chondrodysplasia, such as achondroplasia. With timely diagnosis and appropriate management of complications (e.g., spinal stenosis), affected individuals can lead largely independent lives. Severe forms, however, may be perinatally lethal or associated with significant disability.

References

1. Mortier GR et al. - Nosology and Classification of Genetic Skeletal Disorders: 2019 Revision. American Journal of Medical Genetics Part A, 2019.
2. Orphanet: Chondrodysplasia - Orphanet Encyclopedia. Available at: www.orpha.net (accessed 2024).
3. Superti-Furga A, Unger S - Nosology and Classification of Genetic Skeletal Disorders. American Journal of Medical Genetics Part A, 2007.